OverviewSuggest Edit

Pernix Therapeutics is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. The Company’s pediatric products, designed to improve the health and well-being of children, are focused in the specific areas of allergy, upper respiratory, including nasal, chest congestion and cough, antibiotics and dermatology, including head lice, and contact dermatitis.
TypePublic
Founded1997
HQMorristown, US
Websitepernixtx.com
Employee Ratings2.2

Latest Updates

Employees (est.) (Feb 2019)171
Revenue (FY, 2017)$146.1 M(+4%)
Share Price (Mar 2019)$0.2 (-6%)

Key People/Management at Pernix Therapeutics

Kenneth R. Piña

Kenneth R. Piña

Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary
Angus Smith

Angus Smith

Senior Vice President, Chief Business Officer and Principal Financial Officer
Christopher J. Bordiuk

Christopher J. Bordiuk

Vice President, Human Resources
George P. Jones

George P. Jones

Vice President of Sales and Marketing
Anthony M. Orrico

Anthony M. Orrico

Vice President Supply and Technical Operations
Glenn Whaley

Glenn Whaley

Vice President of Finance, Principal Accounting Officer and Controller
Show more

Pernix Therapeutics Office Locations

Pernix Therapeutics has an office in Morristown
Morristown, US (HQ)
Morristown, NJ 07960, USA
Show all (1)

Pernix Therapeutics Financials and Metrics

Pernix Therapeutics Revenue

Embed Graph
View revenue for all periods
Pernix Therapeutics's revenue was reported to be $146.07 m in FY, 2017
USD

Revenue (Q3, 2018)

37.2m

Gross profit (Q3, 2018)

25.3m

Gross profit margin (Q3, 2018), %

68.2%

Net income (Q3, 2018)

(11.8m)

EBIT (Q3, 2018)

(10.5m)

Market capitalization (4-Mar-2019)

3.0m

Closing stock price (4-Mar-2019)

0.2

Cash (30-Sep-2018)

24.5m

EV

300.9m
Pernix Therapeutics's current market capitalization is $3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

60.6m61.3m84.9m121.7m175.9m140.9m146.1m

Revenue growth, %

43%44%

Cost of goods sold

20.5m23.4m43.9m45.2m51.4m43.3m44.6m

Gross profit

40.1m37.9m41.0m76.6m124.4m97.5m101.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

12.0m17.1m14.5m10.5k18.1k22.1b20.6m18.3m19.1m17.4m31.5m33.9m47.0m48.6m32.5m36.7m41.5m29.7m34.3m40.5m28.1m21.1m37.2m

Cost of goods sold

3.6m7.8m4.7m3.4m7.8m13.1m11.2m9.6m10.0m8.7m11.7m11.1m13.8m12.0m11.2m12.2m10.8m10.0m10.5m10.6m9.0m5.6m11.8m

Gross profit

8.5m9.2m9.8m(3.4m)(7.7m)22.1b9.4m8.7m9.1m8.7m19.8m22.8m33.2m36.6m21.2m24.6m30.6m19.7m23.8m29.9m19.2m15.5m25.3m

Gross profit Margin, %

70%54%68%(32390%)(42691%)100%46%48%48%50%63%67%71%75%65%67%74%66%69%74%68%74%68%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

34.6m23.0m15.6m34.9m56.1m36.4m32.8m

Accounts Receivable

20.6m36.6m25.7m44.1m61.2m50.7m45.3m

Prepaid Expenses

2.1m3.9m5.9m10.3m13.3m10.1m

Inventories

6.3m22.0m13.8m11.4m10.0m7.8m5.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

16.6m27.6m39.2m50.5m37.0m26.3m9.0m9.7m55.9m60.8m16.4m18.9m66.8m57.2m36.6m29.2m28.5m22.7m14.3m27.2m26.9m19.9m24.5m

Accounts Receivable

11.1m23.6m16.4m15.6m20.8m30.6m26.7m23.3m31.9m22.8m51.8m44.8m46.4m60.6m51.8m48.4m44.8m31.0m45.2m48.4m37.0m35.3m66.4m

Prepaid Expenses

1.8m1.7m1.7m2.1m2.3m4.8m4.7m6.7m6.2m6.5m10.5m9.8m17.9m10.1m12.1m11.7m13.3m15.1m13.3m8.8m7.3m6.1m11.9m

Inventories

3.8m7.5m5.0m6.7m7.0m18.3m19.0m16.5m10.8m12.5m11.6m12.7m9.1m10.7m11.8m9.7m8.3m7.4m8.5m8.1m5.4m5.1m17.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

8.3m(1.4m)(25.6m)(35.3m)(148.3m)(169.6m)(77.1m)

Depreciation and Amortization

2.3m3.2m8.7m33.0m94.7m86.1m73.2m

Inventories

(2.1m)650.1k7.4m1.9m444.0k2.3m2.4m

Accounts Payable

739.6k(1.8m)(3.5m)2.1m6.7m(8.0m)(2.1m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

2.5m4.5m1.2m259.4k(10.9k)(8.1m)(14.0m)(20.1m)(9.5m)(15.8m)(27.5m)(23.7m)(55.9m)(66.6m)(25.9m)(57.1m)(83.5m)(29.5m)(51.1m)(44.7m)(18.6m)(32.1m)(43.9m)

Depreciation and Amortization

1.1m1.7m638.1k1.4m2.3m2.2m4.8m7.5m2.2m4.2m14.3m18.4m40.8m66.5m23.7m44.7m65.4m18.5m36.8m55.0m9.9m11.3m13.7m

Inventories

(360.2k)3.4m1.2m(407.2k)190.4k4.8m4.1m4.9m1.8m695.7k1.7m(1.4m)1.4m(182.0k)(1.8m)342.0k1.8m331.0k(707.0k)(355.0k)(11.0k)338.0k3.6m

Accounts Payable

(468.8k)2.5m(738.0k)753.5k83.3k(815.0k)5.8m100.4k2.5m4.4m6.2m(3.6m)(38.0k)15.0m7.5m(4.3m)(7.0m)(1.8m)892.0k(3.0m)(1.9m)(1.7m)(293.0k)
USDY, 2018

EV/EBIT

-28.6 x

EV/CFO

-11.9 x

Debt/Equity

-1.9 x

Debt/Assets

1.2 x

Financial Leverage

-1.6 x
Show all financial metrics

Pernix Therapeutics Online and Social Media Presence

Embed Graph

Pernix Therapeutics News and Updates

Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®

MORRISTOWN, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), announced today that, on September 7, 2018, its subsidiaries, Pernix Therapeutics, LLC, a specialty pharmaceutical company, and Pernix Ireland Pain Designated Activity Company, filed a notice of …

Pernix Therapeutics Announces a Series of Transactions to Strengthen Its Balance Sheet and Improve Financial Flexibility

MORRISTOWN, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announces a series of transactions aimed at strengthening its balance sheet and improving financial flexibility, as described below.

Pernix Therapeutics Frequently Asked Questions

  • When was Pernix Therapeutics founded?

    Pernix Therapeutics was founded in 1997.

  • Who are Pernix Therapeutics key executives?

    Pernix Therapeutics's key executives are Kenneth R. Piña, Angus Smith and Christopher J. Bordiuk.

  • How many employees does Pernix Therapeutics have?

    Pernix Therapeutics has 171 employees.

  • What is Pernix Therapeutics revenue?

    Latest Pernix Therapeutics annual revenue is $146.1 m.

  • What is Pernix Therapeutics revenue per employee?

    Latest Pernix Therapeutics revenue per employee is $854.2 k.

  • Who are Pernix Therapeutics competitors?

    Competitors of Pernix Therapeutics include Moderna Therapeutics, Alnylam Pharmaceuticals and Celyad.

  • Where is Pernix Therapeutics headquarters?

    Pernix Therapeutics headquarters is located at Morristown, NJ 07960, USA, Morristown.

  • Where are Pernix Therapeutics offices?

    Pernix Therapeutics has an office in Morristown.

  • How many offices does Pernix Therapeutics have?

    Pernix Therapeutics has 1 office.